BioAge Labs Announces Pricing of Upsized Initial Public Offering
WEBRICHMOND, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of aging, today announced the pricing of its.
BioAge prices $198M IPO, validating pivot to obesity drug research
WEB6 days ago · BioAge Labs has raised $198 million in an initial public offering, the company announced Wednesday, capitalizing on intense investor interest in drugs that can promote weight loss.
BioAge brings in $198M from IPO as obesity biotech joins Nasdaq
WEB5 days ago · BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its lead obesity drug further into clinical trials.
BioAge Labs Announces Pricing of Upsized Initial Public Offering
WEB5 days ago · RICHMOND, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...
BioAge Labs IPO: stock price today in high-profile Nasdaq debut
WEB5 days ago · BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq. The California-based biotech priced its shares at $18. Its lead product, a...
Weight loss drug maker BioAge Labs eyes $200 million IPO - Quartz
WEB5 days ago · BioAge Labs, a biopharmaceutical startup focused on obesity drugs, is looking to raise nearly $200 million in its recently expanded, planned initial public offering, according to a filing with...
Obesity drug developer BioAge Labs aims up to $640 mln …
WEB5 days ago · BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand...
BioAge Labs: Weighing The Risks And Rewards Of A Biotech Revival
WEB16 hours ago · BioAge Labs' IPO success, with a 30% stock surge and $198 million raised, exemplifies the biotech sector's recovery and investor optimism.
BioAge Labs Files For $100M IPO, Becomes The New Entrant In …
WEBSep 4, 2024 · BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering. The company was founded in 2015...
BioAge Labs Files for IPO to Be Led by Goldman, Morgan Stanley
WEBSep 3, 2024 · BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, has filed for an initial public offering.
- Some results have been removed